The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression

Transcription

Volumn 4, Issue 1, 2013, Pages 24-28

  Chang, Suhwan ^a,b   Sharan, Shyam K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

BRCA1; Breast cancer; Epigenetic regulation; micro RNA; miR 155; Transcription

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; FANCONI ANEMIA GROUP D2 PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MICRORNA; MICRORNA 155; MICRORNA 652; MYC PROTEIN; NUCLEOPLASMIN; PROGESTERONE RECEPTOR A; PROTEIN P53; RNA POLYMERASE II; SUPPRESSOR OF CYTOKINE SIGNALING 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; HUMAN; NONHUMAN; OVARY CANCER; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 84872201806     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.22600     Document Type: Article

References (39)

1. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7:937-48; PMID:18034184; http://dx.doi.org/10.1038/nrc2054.
2. Li ML, Greenberg RA. Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci 2012; 37:418-24; PMID:22836122; http://dx.doi.org/10.1016/j.tibs.2012.06.007.
3. Wang B. BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci 2012; 2:6; PMID:22369660; http://dx.doi.org/10.1186/2045-3701-2-6.
4. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010; 31:961-7; PMID:20400477; http://dx.doi.org/10.1093/carcin/bgq069.
5. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996; 14:430-40; PMID:8944023; http://dx.doi.org/10.1038/ng1296-430.
6. Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 2002; 12:86-91; PMID:11790560; http://dx.doi.org/10.1016/S0959-437X(01)00269-6.
7. Wu W, Koike A, Takeshita T, Ohta T. The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div 2008; 3:1; PMID:18179693; http://dx.doi.org/10.1186/1747-1028-3-1.
8. Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, et al. BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature 2011; 477:179-84; PMID:21901007; http://dx.doi.org/10.1038/nature10371.
9. Reid LJ, Shakya R, Modi AP, Lokshin M, Cheng JT, Jasin M, et al. E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci U S A 2008; 105:20876-81; PMID:19088202; http://dx.doi.org/10.1073/pnas.0811203106.
10. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science 2011; 334:525-8; PMID:22034435; http://dx.doi.org/10.1126/science.1209909.
11. rd, Fukuda M, et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 2003; 100:5646-51; PMID:12732733; http://dx.doi.org/10.1073/pnas.0836054100.
12. Sato K, Sundaramoorthy E, Rajendra E, Hattori H, Jeyasekharan AD, Ayoub N, et al. A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair. Curr Biol 2012; 22:1659-66; PMID:22863316; http://dx.doi.org/10.1016/j.cub.2012.07.034.
13. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 1996; 93:13595-9; PMID:8942979; http://dx.doi.org/10.1073/pnas.93.24.13595.
14. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996; 382:678-9; PMID:8751436; http://dx.doi.org/10.1038/382678a0.
15. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997; 94:5605-10; PMID:9159119; http://dx.doi.org/10.1073/pnas.94.11.5605.
16. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25:5854-63; PMID:16998500; http://dx.doi.org/10.1038/sj.onc.1209872.
17. Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett 2006; 236:175-85; PMID:15975711; http://dx.doi.org/10.1016/j.canlet.2005.04.037.
18. Aiyar SE, Cho H, Lee J, Li R. Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells. Int J Biol Sci 2007; 3:486-92; PMID:18071589; http://dx.doi.org/10.7150/ijbs.3.486.
19. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A 2002; 99:7560-5; PMID:12032322; http://dx.doi.org/10.1073/pnas.062181799.
20. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65:10265-72; PMID:16288014; http://dx.doi.org/10.1158/0008-5472.CAN-05-1841.
21. Satih S, Chalabi N, Rabiau N, Bignon YJ, Bernard-Gallon DJ. Transcriptional profiling of breast cancer cells exposed to soy phytoestrogens after BRCA1 knockdown with a whole human genome microarray approach. Nutr Cancer 2010; 62:659-67; PMID:20574927; http://dx.doi.org/10.1080/01635581003605540.
22. Gorski JJ, Savage KI, Mulligan JM, McDade SS, Blayney JK, Ge Z, et al. Profiling of the BRCA1 transcriptome through microarray and ChIP-chip analysis. Nucleic Acids Res 2011; 39:9536-48; PMID:21880590; http://dx.doi.org/10.1093/nar/gkr679.
23. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999; 96:4983-8; PMID:10220405; http://dx.doi.org/10.1073/pnas.96.9.4983.
24. Chai YL, Cui J, Shao N, Shyam E, Reddy P, Rao VN. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 1999; 18:263-8; PMID:9926942; http://dx.doi.org/10.1038/sj.onc.1202323.
25. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102:257-65; PMID:10943845; http://dx.doi.org/10.1016/S0092-8674(00)00030-1.
26. Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res 2010; 70:2538-47; PMID:20215511; http://dx.doi.org/10.1158/0008-5472.CAN-09-2089.
27. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, et al.; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011; 17:1275-82; PMID:21946536; http://dx.doi.org/10.1038/nm.2459.
28. Tam W, Ben-Yehuda D, Hayward WS. bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol 1997; 17:1490-502; PMID:9032277.
29. Tam W, Dahlberg JE. miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer 2006; 45:211-2; PMID:16252262; http://dx.doi.org/10.1002/gcc.20282.
30. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103:7024-9; PMID:16641092; http://dx.doi.org/10.1073/pnas.0602266103.
31. Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, et al.; kConFab; Dutch Belgium UV Consortium; German Consortium of Hereditary Breast and Ovarian Cancer; French COVAR group collaborators; ENIGMA Consortium. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012; 49:525-32; PMID:22889855; http://dx.doi.org/10.1136/jmedgenet-2012-101037.
32. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004; 11:512-8; PMID:15133502; http://dx.doi.org/10.1038/nsmb775.
33. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316:604-8; PMID:17463289; http://dx.doi.org/10.1126/science.1141229.
34. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316:608-11; PMID:17463290; http://dx.doi.org/10.1126/science.1139253.
35. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 2007; 104:12111-6; PMID:17626182; http://dx.doi.org/10.1073/pnas.0702969104.
36. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28:264-84; PMID:19811312; http://dx.doi.org/10.1080/08830180903093796.
37. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70:3119-27; PMID:20354188; http://dx.doi.org/10.1158/0008-5472.CAN-09-4250.
38. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71; PMID:7545954; http://dx.doi.org/10.1126/science.7545954.
39. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212.